^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QH104

    i
    Other names: QH104, B7H3 CAR-γδT, QH-104, QH 104
    Associations

    News

    Trials
    Company:
    Beijing Qinghui Liannuo Biotechnology, Suzhou Dushu Lake Hospital
    Drug class:
    γδ TCR modulator, B7-H3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    4ms
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Dushu Lake Hospital Affiliated to Soochow University | Suspended --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    QH104
    1year
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
    P1/2, N=25, Suspended, Dushu Lake Hospital Affiliated to Soochow University | Recruiting --> Suspended
    Trial suspension
    |
    CD276 (CD276 Molecule)
    |
    CD276 expression
    |
    QH104
    over2years
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Dushu Lake Hospital Affiliated to Soochow University
    New P1/2 trial
    |
    IL6 (Interleukin 6) • CD276 (CD276 Molecule) • IL10 (Interleukin 10)
    |
    CD276 expression
    |
    QH104